CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS

被引：0
|
作者：
Hiken, Eliah J. [1 ]
Poweleit, Ethan A. [1 ]
Keane, Corey [1 ]
Desta, Zeruesenay [1 ]
Strawn, Jeffrey R. [1 ]
Ramsey, Laura B.
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY | 2023年 / 62卷 / 10期
关键词：
D O I：
10.1016/j.jaac.2023.09.140
中图分类号：
B844 [发展心理学（人类心理学）];
学科分类号：
040202 ;
摘要：
2.53
引用
收藏
页码：S197 / S197
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics and tolerability of atomoxetine in adults of known CYP2D6 phenotype.
    Witcher, J
    Long, A
    Sauer, JM
    Smith, B
    Read, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P27 - P27
  • [42] Effect of CYP2D6 phenotype and metoprolol pharmacokinetics on adverse effects.
    Beitelshees, AL
    Zineh, I
    Gaedigk, A
    Leeder, JS
    Walker, JR
    Eberst, K
    Timmerbeil, BS
    Lobmeyer, M
    Pauly, DF
    Johnson, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P94 - P94
  • [43] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [44] Molecular analysis of the CYP2D6*41 "intermediate metabolizer" allele
    Toscano, C
    Raimundo, S
    Klein, K
    Schaeffeler, E
    Eichelbaum, M
    Schwab, M
    Zanger, UM
    DRUG METABOLISM REVIEWS, 2004, 36 : 116 - 116
  • [45] Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
    Susce, Margaret T.
    Murray-Carmichael, Elaina
    de Leon, Jose
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (07): : 1356 - 1358
  • [46] Unique case of serotonin toxicity in a poor CYP2D6 metabolizer
    Feininger, E. Sterling
    Dulaney, Anna
    Sanders, Taylor
    Pikus, Angela
    Kopec, Kathryn
    CLINICAL TOXICOLOGY, 2023, 61 : 71 - 71
  • [47] Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status
    Barclay, ML
    Sawyers, SM
    Begg, EJ
    Zhang, M
    Roberts, RL
    Kennedy, MA
    Elliott, JM
    PHARMACOGENETICS, 2003, 13 (10): : 627 - 632
  • [48] ASSOCIATION OF CYP2D6 METABOLIZER STATUS WITH ANTIDEPRESSANT INDUCED MANIA
    Beaupre, Lindsay Melhuish
    Zai, Clement
    Tiwari, Arun
    Mundo, Emanuela
    Shaikh, Sajid
    Tampakeras, Maria
    Freeman, Natalie
    Kennedy, James L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S865 - S865
  • [49] Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
    Kneller, Lisa Alina
    Zubiaur, Pablo
    Koller, Dora
    Abad-Santos, Francisco
    Hempel, Georg
    CLINICAL PHARMACOKINETICS, 2021, 60 (12) : 1569 - 1582
  • [50] Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
    Lisa Alina Kneller
    Pablo Zubiaur
    Dora Koller
    Francisco Abad-Santos
    Georg Hempel
    Clinical Pharmacokinetics, 2021, 60 : 1569 - 1582
12345